Benzinga Cannabis Hour Recap: Skye Bioscience CEO Discusses How Cannabinoids May Treat Glaucoma

Cannabinoid receptors distributed within the body are part of the endocannabinoid system that largely affects processes such as mood, memory, -sensation, and appetite, to name a few.

Two types of receptors — CB1 and CB2 — “play a vital role in managing different body functions,” Skye Bioscience Inc.’s (OTCQB: SKYE) president and CEO Punit Dhillon explains on the most recent edition of the Cannabis Hour.

As the most common cannabinoids, THC and CBD are both able to bind to these receptors. See video below.

Skye Bioscience is establishing itself in the …

Full story available on Benzinga.com

More Benzinga Cannabis Hour Recap: Skye Bioscience CEO Discusses How Cannabinoids May Treat Glaucoma